CYP3A4 breaks down drugs that treat various health conditions, including the anti-cancer agent paclitaxel and the COVID-19 therapeutic nirmatrelvir. CYP3A4 inhibitors are commonly co-administered to ...

CYP3A4 breaks down drugs that treat various health conditions, including the anti-cancer agent paclitaxel and COVID-19 therapeutic nirmatrelvir. CYP3A4 inhibitors are commonly co-administered to ...

Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin. It was approved in April 2022 for the treatment of adults with symptomatic New York Heart Association (NYHA) class ...

SaveHealth assesses the relative benefits of Zoloft vs. Lexapro, comparing their usage, effectiveness, tolerability, ...

Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindication ...

FDA approves Camzyos label update easing echo monitoring and lifting drug interaction limits, supported by 3.5 years of safety data and real-world use ...

Potentiated by CYP3A4 inhibitors (eg, ketoconazole ... Monitor for hypokalemia with potassium-depleting drugs (eg, amphotericin B, diuretics). Toxic epidermal necrolysis possible with thalidomide.

The simplified requirements for Camzyos are expected to ease prior contraindications, thereby simplifying treatment and ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has updated the U.S.